Aptadel Therapeutics
Aptadel Therapeutics is a biotech company focused on the development of cancer treatment based on aptamer technology.
Aptadel Therapeutics is a biotech company focused on the development of cancer treatment based on aptamer technology.
Aptadel Therapeutics is a preclinical-stage biotech company based in Barcelona, Spain with a strong focus on developing cancer treatments utilizing aptamer technology. The company's lead indication is Ewing Sarcoma, a rare form of bone cancer primarily affecting children. Established in 2020, Aptadel Therapeutics recently received a €1.70M investment in a Seed Round, with Alba Pérez Foundation being the lead investor, marking a significant milestone. This biotech startup operates in the Biotechnology and Health Care industries with a goal to revolutionize cancer treatment through its RNA-based delivery platform. With its innovative approach and dedicated team, Aptadel Therapeutics stands at the forefront of the biotech sector, aiming to make a positive impact on cancer therapy.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €1.70M | 1 |
|
21 Jan 2021 |
No recent news or press coverage available for Aptadel Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
